Status:
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
Lead Sponsor:
SWOG Cancer Research Network
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
ATM Gene Mutation
ATR Gene Mutation
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after ...
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) with talazoparib (BMN 673) in HRRD Medivation (MDVN)-positive patients. SECONDARY...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
- Patients must be assigned to S1400G; S1400G biomarker eligibility defined as homologous recombination repair deficiency (HRRD) positive is as follows
- Biomarker-positive group
- HRRD by FMI
- Homologous recombination repair deficiency by Foundation Medicine Inc., criteria
- Alteration type
- Truncating mutation, frameshift deletions, indels missense and nonsense mutations predicted to have functional consequence in any of the specified genes
- Eligible alteration
- Mutation in any one of the following critical HRR pathway genes: ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCF, FANCM, NBN (NBS1), PALB2, RAD51, RAD51B (RAD51L1), RAD54L, RPA1
- Patients must not have had prior exposure to any agent with a PARP inhibitor (e.g., veliparib, olaparib, rucaparib, niraparib, talazoparib \[BMN 673\]) as its primary pharmacology
- Patients must have achieved stable disease, a partial response, or a complete response at their first disease assessment after initiating first-line platinum-based chemotherapy; patients determined to have progressed (in the opinion of the treating physician) at their first disease assessment are not eligible
- Patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of talazoparib (BMN 673) (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or active peptic ulcer disease); patients must not have active small or large intestine inflammation such as Crohn's disease or ulcerative colitis (within 12 months of sub-study registration)
- Patients must be able to take oral medications; patients must be able to swallow capsules whole without crushing or altering them in any way
- Patients must not be taking, nor plan to take while on protocol treatment strong P-glycoprotein (P-gp) inhibitors, P-gp inducers, or breast cancer resistance protein (BCRP) inhibitors; the language ?P-gp or BCRP inhibitors or inducers? is reworded to ?strong P-gp inhibitors, P-gp inducers, or BCRP inhibitors? for consistency with the investigator brochure
- Patients must agree to have blood specimens submitted for pharmacokinetic analysis
Exclusion
Key Trial Info
Start Date :
March 3 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 16 2021
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT03377556
Start Date
March 3 2017
End Date
April 16 2021
Last Update
June 23 2021
Active Locations (1157)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States, 35233
2
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States, 98508
3
Anchorage Radiation Therapy Center
Anchorage, Alaska, United States, 99504
4
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States, 99508